Long-term follow-up for A2 Bio gene therapy patients
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received at least one dose of an A2 Bio gene therapy product in a previous A2 Bio study.
- You must be willing and able to sign a consent form for this follow-up study.
- You must be able to follow the study's instructions and schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a long-term follow-up for people who have already received a cell or gene therapy in a previous AstraZeneca trial. It helps researchers monitor your health over time to make sure the therapy is safe and effective.
This study is for people who have already received a special kind of cell therapy that involved modifying their genes. The purpose is to keep track of their health over a longer period of time to see how they are doing after the treatment.
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
This study checks how people do over the long term after receiving CAR-T, an advanced immune treatment. It may help doctors understand long-term safety and benefits, and what to expect after treatment.
This study follows people for many years after they receive gene therapy (a treatment that uses lab-made genetic material). It mainly checks long-term safety and health outcomes and may help doctors understand how gene therapy works over time.
This study follows people long-term after receiving a specific gene-cell treatment called AGT103-T. It helps researchers check long-term safety and outcomes, which can guide future care for others.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.